Biomea Fusion Reveals Lasting Success for Short-Term Type 1 Diabetes Treatment
Redwood City, Monday, 27 April 2026.
Biomea Fusion’s icovamenib boosted natural insulin markers by 52%. Remarkably, this unprecedented benefit in Type 1 diabetes patients persisted for a full year following just a 12-week treatment.
Unpacking the COVALENT-112 Trial Data
On April 26 and 27, 2026, clinical-stage biopharmaceutical company Biomea Fusion (Nasdaq: BMEA) released the 52-week outcomes from its Phase 2 COVALENT-112 clinical trial [1][2]. The open-label study evaluated icovamenib, an investigational oral small-molecule drug, in adult patients aged 18 to 60 with Stage 3 Type 1 diabetes [1][2]. Participants were divided based on their disease duration: those diagnosed within zero to three years, and those diagnosed between three and fifteen years [1][2]. Patients received daily doses of either 100 milligrams or 200 milligrams of icovamenib over a 12-week period, followed by a 40-week observation phase [1][2].